00:46 , May 11, 2019 |  BioCentury  |  Product Development

Now grown up, independent biotechs bulk up their platforms with more modalities

As the incoming class of independent biotechs look to build on their clinical and commercial successes, a handful are expanding beyond the technology that got them there, bringing in new modalities to complement their platforms...
23:28 , Mar 27, 2019 |  BC Extra  |  Financial News

Elicio raises $30M to target cancer vaccines to the lymph nodes

Elicio launched Wednesday with $30 million in funding and an immunotherapy strategy aimed at getting cancer vaccines into the lymph nodes, a location that orchestrates immune responses but has been hard to target directly. Elicio...
04:16 , Jan 4, 2019 |  BC Week In Review  |  Financial News

Cellid proposes Korean IPO

Cell-based vaccine company Cellid Co. Ltd. (Seoul, South Korea) proposed on Dec. 13 to sell 1.2 million shares at W22,100-W27,000 in a Korean IPO, according to the Korean Stock Exchange's website. At the W24,550 mid-point,...
21:16 , Nov 9, 2018 |  BC Week In Review  |  Company News

Cue, LG in biologics deal

Cue Biopharma Inc. (NASDAQ:CUE) granted LG Chem Life Sciences exclusive development and commercialization rights in certain Asian-Pacific countries, including Japan, China and Korea, and Australia to CUE-101 and Cue's Immuno-STAT biologics that target T cells...
20:24 , Oct 31, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer; infectious disease

INDICATION: Cancer; melanoma; cervical cancer; influenza virus Mouse and monkey studies suggest simvastatin could be used as an adjuvant to boost the efficacy of cancer and influenza vaccines. In mice, immunization with the antigen ovalbumin...
17:38 , Sep 26, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Cervical cancer; lung cancer; ovarian cancer Patient sample, cell culture and mouse studies suggest promoting ATP5H expression or inhibiting reactive oxygen species (ROS) could help treat therapy-resistant cancers. In tumor samples from patients with...
17:53 , Aug 29, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Cervical cancer; skin cancer Mouse studies suggest a vaccine based on a nanoparticle-HpV16gp2 peptide conjugate could help treat human papillomavirus (HPV)-associated cancers. The conjugate consists of nanoparticles with a polypropylene sulfide core and HpV16gp2...
18:53 , Jul 13, 2018 |  BC Week In Review  |  Clinical News

FDA lifts hold on Phase I/II of axalimogene filolisbac for SCCHN

Advaxis Inc. (NASDAQ:ADXS) said FDA lifted a clinical hold on a Phase I/II combination study that includes the company's axalimogene filolisbac (ADXS11-001). The trial is evaluating the therapy in combination with PD-L1 inhibitor Imfinzi durvalumab...
16:24 , Jul 13, 2018 |  BC Extra  |  Clinical News

Advaxis rises after FDA lifts clinical hold

Advaxis Inc. (NASDAQ:ADXS) jumped $0.12 (10%) to $1.34 Friday after it said FDA lifted a clinical hold on a Phase I/II combination study that includes the company's axalimogene filolisbac (ADXS11-001). The trial is evaluating the...
15:12 , Jun 8, 2018 |  BC Week In Review  |  Clinical News

Kite reports data for TCR therapy in HPV-positive solid tumors

The Kite Pharma Inc. subsidiary of Gilead Sciences Inc. (NASDAQ:GILD) reported data from seven evaluable patients with metastatic HPV-16-positive solid tumors in the NCI-sponsored Phase I 16-C-0154 trial showing that a single infusion of a...